Unique methylation pattern of oncostatin M receptor gene in cancers of colorectum and other digestive organs

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1519-1526

  Deng, Guoren ^a,c   Kakar, Sanjay ^b   Okudiara, Keisuke ^a   Choi, Esther ^a   Sleisenger, Marvin H ^a   Kim, Young S ^a  

^a Gastrointestinal Research Laboratory (151M2)   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 1; HISTONE H3; MESSENGER RNA; ONCOSTATIN M RECEPTOR; SMALL INTERFERING RNA; TRICHOSTATIN A;

ACETYLATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DNA METHYLATION; FEMALE; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MALE; MELANOMA; PANCREAS CANCER; POLYMERASE CHAIN REACTION; POLYP; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER;

ACETYLATION; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GASTROINTESTINAL TRACT; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; ONCOSTATIN M RECEPTOR BETA SUBUNIT; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63449113180     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1778     Document Type: Article

References (27)

1. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN,Todaro GJ. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A 1986;83: 9739-43.
2. Grant SL, Begley CG, The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today1999;5:406-12.
3. Douglas AM, Grant SL, Goss GA, Clouston DR, Sutherland RL, Begley CG. Oncostatin M induces the differentiation of breast cancer cells. Int J Cancer 1998;75:64-73.
4. Tanaka M, Miyajima A, Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003;149:39-52.
5. Bellido T, Borba VZ, Roberson P. Manolagas SC. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promoter osteoblast differentiation. Endocrinology 1997;138: 3666-76.
6. Chipoy C, Brounais B, Trichet V, et al. Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene 2007;26: 6653-64.
7. Mosley B, Imust CD, Friend D, et al. Dual oncostatin M (OSM) receptors. J Biol Chem1996;271: 32635-43.
8. Underhill-Day N, Heath JK. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor β-specific kernel. Cancer Res 2006; 66:10891 -901.
9. Lacreusette A, Nguyen J-M, Pandolfino M-C, et al. Loss of oncostatin M receptor β in metastatic melanoma cells. Oncogene 2007;26:881 -92.
10. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibitor in colorectal cancer. Nat Genet 2002;31:141-9.
11. Suzuki H, Watkins DN, Jair K-W, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36: 417-22.
12. Mori Y, Cai K, Cheng Y, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1 and five other genes in colon cancer. Gastroenterology 2006;131:797 -808.
13. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodiumtransporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A 2003;100: 8412-7.
14. Toyota M, Ahuju N, Ohe-Toyota M, Herman JG, Baylin SB, Issa IP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A1999; 96:8681 -6.
15. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837 -45.
16. Deng G, Peng E, Gum J, Terdiman J, Sleisenger M, Kim YS. Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. BrJ Cancer 2002;86:574-9.
17. Deng G, Nguyen A, Tanaka H, et al. Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int J Cancer 2006; 118:2999 -3005.
18. Deng G, Chen A, Hong J, Chae HS, KimYS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res1999;59:2029 -33.
19. Deng G, Kakar S, Tanaka H, et al. Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. EurJ Cancer 2008;44:1290-301.
20. Shen L, Toyota M, Kondo Y, et al. Integrated geneticand epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007;104:18654-9.
21. Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT. Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol 2003;162: 815 -22.
22. Rashid A, Shen L, MorrisJS, Issa JP, Hamilton SR. CpG island methylation in colorectal adenomas. Am J Pathol 2001;159:1129 -35.
23. Kim YH, Petko Z, Dzieciatkowski S, et al. CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 2006;45:781 -9.
24. Kakar S, Deng G, Cun L. Sahai V, Kim YS. CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum Pathol 2008;39:30-6.
25. Konishi K, Shen L,Wang S, Meltzer SJ, Harpaz N, Issa JP. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology 2007;132:1254-60.
26. Yoshizawa S, Matsuoka K, Inoue N, et al. Clinical significance of serump53 antibodies in patients with ulcerative colitis and its carcinogenesis. Inflamm Bowel Dis 2007;13:865 -73.
27. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-8.